Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

Jesse’s Journey Welcomes New Executive Director

We have a new leader of the team here at Jesse’s Journey.   We are pleased to announce that Perry Esler will be assuming the role of Executive Director on October 1st. Perry is no stranger to Jesse’s Journey, having been on the road with us in 1995. He comes to us with more than […]


Canadian Collaboration Gives Funding Boost to Duchenne MD Research

AbCellera Biologics Inc. has announced a collaboration with Fabio Rossi, MD, PhD, and Michael Underhill, PhD, of the University of British Columbia, to develop therapeutic antibodies for the treatment of Duchenne muscular dystrophy-associated fibrosis. “It is immensely satisfying to see many years of investment in the basic science now being translated towards therapies for patients in need, and […]


PTC Study 041 Canadian trial sites

PTC Therapeutics has announced three Canadian sites for their clinical trial known as Study 041 for Duchenne muscular dystrophy.  Study 041 is looking at how the investigational treatment, ataluren, affects ability to walk and endurance in males aged five years and older with nmDMD, compared to placebo. More information about the study can be found by clicking here […]


Rick Moss Appointed to the CORD Board of Directors

I am very happy to share with you today the news that Rick Moss, our Director of Advocacy and Partnerships, has joined the Board of Directors of the Canadian Organization for Rare Disorders (CORD). Over the past two years Rick has been working diligently on behalf of Jesse’s Journey in the area of advocacy with […]


15th annual Tory’s Tourney

Last weekend was the 15th annual Tory’s Tourney for Jesse’s Journey, hosted by the Provenzano family in Windsor. It was another sold-out tournament – over the last 15 years, this amazing event has raised more than $400,000 for Duchenne muscular dystrophy research. And they’ve never been rained out! (knock on wood). Representing Jesse’s Journey were […]


First Patient Enrolled in Phase 2 Trial of MNK-1411, Mallinckrodt’s Investigational Therapy for DMD

The first patient has been enrolled in a Phase 2 trial evaluating the effectiveness and safety of MNK-1411, an investigational therapy for Duchenne muscular dystrophy (DMD), announced Mallinckrodt Pharmaceuticals, the treatment’s developer. The company also reported that MNK-1411 was granted orphan medicinal product status by the European Medicines Agency, facilitating the development and eventually the approval process for the treatment candidate. The therapy was given orphan drug designation in […]


A Note from John Davidson, August 9th

20-years-ago-today was my 122nd day on the road and I had reached London, my home town. It had been four months since I dipped the toes of my running shoes in the cold water of the Atlantic Ocean in St. John’s, Newfoundland and set out to walk across Canada at the age of 52. There’s […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.